CalciMedica reports $14.6M cash; Auxora shows 53% hospital stay reduction in CRSPA cohort

CalciMedica, Inc.

Preliminary cash, equivalents, and short-term investments of $14.6M as of Sept 30, 2023; expected to fund operations through Q3 2024.
Auxora (zegocractin) reduced average hospital stay from 13.4 to 6.3 days (53% reduction) in initial cohort of CRSPA study vs historical control.
No patients treated with Auxora required total parenteral nutrition (TPN) vs 68.8% in control.
Recommended dose established for children with ALL experiencing asparaginase-associated pancreatitis: dose level 1.
Data to be presented at ASH Meeting Dec 9-12, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.